Clinical Research Directory

Inclusion Criteria: * Males or females aged ≥ 18 years. * Ability to understand and willingness to sign a written informed consent document. * Patients must have a histologically or cytologically confirmed metastatic or unresectable malignancy. * Estimated life expectancy, in the judgment of the Investigator, of at least 90 days. * Adequate bone marrow, liver, and renal functions * Men and women of childbearing potential must agree to take highly effective contraceptive methods. * Patients should recover from all reversible AEs of previous anticancer therapies to baseline. * Patients infected with the HIV virus will be eligible if the disease is under control of effective therapy. Exclusion Criteria: * Prior therapy with anti-CD40 therapy. * Receipt of systemic anticancer therapy or radiotherapy within certain period of time. * Prior exposure to immune-therapeutics experienced Grade ≥ 3 drug-related toxicity, or a toxicity requiring discontinuation. * Received a live-virus vaccine within 30 days of the first dose of study drug. * Grade ≥ 3 allergic reaction to treatment with a monoclonal antibody. * History of Grade ≥ 3 immune-related AEs (irAEs). * Prolonged QT syndrome, or clinically significant cardiac condition. * Receiving an immunologically based treatment for any reason. * History or current active or chronic autoimmune disease. * Uncontrolled pleural effusion, pericardial effusion, or recurrent ascites drainage. * Female patients who are pregnant or breastfeeding. * History of hemorrhagic or ischemic stroke within the last 6 months. * Previously received an allogeneic tissue/organ transplant, stem cell or bone marrow transplant or solid organ transplant.